PR Newswire

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with adva…

Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and ...
BioSpace

Subcutaneous RYBREVANT® (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

Expert and company perspectives on the role of amivantamab in advancing first-line treatment “Patients with recurrent or metastatic head and neck cancer continue to face a poor prognosis, highlighting ...

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and ...

Media Release COPENHAGEN, Denmark; Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD ...

Light Chain Bioscience – Novimmune SA: Long-term Follow-up of NI-1801 in Platinum Resistant Ovarian Cancer Shows Durable Survival Benefit at 24 Months

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to ...
BioSpace

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-ris…

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
MarketScreener

Bayer : Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

Asundexian is the first approved FXIa inhibitor worldwide. It selectively inhibits FXIa, allowing to reduce pathological clot formation, with similar incidence of all bleeding events between the two ...